All News
Market-leaded Research Development and Innovation Support
Avidin together with partner Synaptogenex awarded with Market-leaded Research Development and Innovation Support 20.01.2020 Project title: Development, testing and production of active compounds and functional
Molecules announces enantioselective synthesis of Q134R, the powerful hypoxic adaptation inducer
Avidin publishes in Molecules the enantioselective synthesis of 8-hydroxyquinoline derivative, Q134 which is a hypoxic adaptation inducer 11.19.2019 Hypoxia is a common feature of neurodegenerative
PharmaOnline reported on Avidin’s unique drug candidate
Unique drug candidate being developed against Alzheimer’s disease reported by PharmaOnline (Hungarian) It has three mechanisms of action on important pathways of Alzheimer’s disease at
EUREKA Innovation collaboration kick-off in Frankfurt
GenXPro Has Organized The Kick-Off Meeting For EUREKA (E!12655 MITOME) Innovation Collaboration With Partners Avidin And Steinbeis-Innovationszentrum Zellkulturtechnik (SIZ) In Frankfurt Monday 23. 09. /
Avidin in Cells’ on Non-Small Cell Lung Cancer
Avidin participated in work on single cell mass cytometry of non-small cell lung cancer published in cells 09.16.2019 Single cell genomics and proteomics with the
Anti-inflammatory research
AVIDIN synthetized Mannich curcuminoids, C142 and C150 showed potent anti-inflammatory properties, Special focus on …
New patent granted in U.S.A.
Enantiomers of lead compounds for neurodegenerative diseases has been granted in the U.S.A. Avidin’s patent, entitled ‘Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis’ was
BIO2019 Convention in Philadelphia (PA)
Avidin’s CEO László Puskás and Head of International Relations Klára Kitajka are participating at BIO 2019 …
Alzheimer’s & Parkinson’s Diseases Congress-Lisbon
Poster in the 14th international conference on Alcheimer’s and Parkinson’s diseases and related neurological disorders